TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02647281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3389404
Description: GSK3389404 is supplied as solution for injection vial. Each vial contains 100 mg/mL of GSK3389404. It's physical appearance is clear colourless to slightly yellow solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3389404
Description: GSK3389404 is supplied as solution for injection vial. Each vial contains 100 mg/mL of GSK3389404. It's physical appearance is clear colourless to slightly yellow solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3389404
Description: GSK3389404 is supplied as solution for injection vial. Each vial contains 100 mg/mL of GSK3389404. It's physical appearance is clear colourless to slightly yellow solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3389404
Description: GSK3389404 is supplied as solution for injection vial. Each vial contains 100 mg/mL of GSK3389404. It's physical appearance is clear colourless to slightly yellow solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3389404
Description: GSK3389404 is supplied as solution for injection vial. Each vial contains 100 mg/mL of GSK3389404. It's physical appearance is clear colourless to slightly yellow solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3389404
Description: GSK3389404 is supplied as solution for injection vial. Each vial contains 100 mg/mL of GSK3389404. It's physical appearance is clear colourless to slightly yellow solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3389404
Description: GSK3389404 is supplied as solution for injection vial. Each vial contains 100 mg/mL of GSK3389404. It's physical appearance is clear colourless to slightly yellow solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo is supplied as solution for injection vial. It's physical appearance is clear colourless solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo is supplied as solution for injection vial. It's physical appearance is clear colourless solution.
Study: NCT04235140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM/IVA
Description: LUM/IVA granules for oral administration
Study: NCT03904017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: 100% Oxygen air

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: medical air
Study: NCT04620785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: methylene blue / IPL
Description: therapeutic

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IPL
Description: therapeutic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: placebo
Study: NCT00315926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin 50 mg during surgery and 10 mg every night for 3 nights

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a mixture of ethanol and physiological saline
Study: NCT01751061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision aid
Description: A web-based decision aid to assist surrogate decision makers in prolonged mechanical ventilation decisions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: usual ICU care
Study: NCT02490735

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-induced Killer Cells
Description: chemotherapy plus 3 cycles of Cytokine-induced Killer Cells(CIK) treatment
Study: NCT02537977

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-directed CAR-T cells
Description: CD19-directed CAR-T cell infusion will be given by vein
Study: NCT00248625

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: The study drug is administered as a continuous infusion at a dose of 150 mg/kg/day for up to 7 days following entry into the study. The infusion is discontinued at the time of death, liver transplant or discharge.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible children were adaptively allocated within strata defined by age (less than 2 years of age or at least 2 years old) and hepatic encephalopathy (grade 0-1 or 2-4) to receive N-acetylcysteine (150 mg/kg/d) in 5% dextrose (D5W) and water or placebo consisting of an equal volume of D5W alone. Volumes were adjusted for small children. Study medications were infused over 24 hours for up to 7 consecutive days in a dedicated line without other medications. Treatment was stopped earlier than 7 days in the case of hospital discharge, liver transplantation, or death within 7 days of randomization.
Study: NCT00698854

Intervention type: DEVICE
Intervention: Vanguard™ Complete Knee System
Description: Primary Total Knee System, Cruciate-Retaining (CR) or Posterior-Stabilized (PS)

Intervention type: DEVICE
Intervention: Vanguard™ Patient-Specific Femur
Description: Primary Total Knee System used with Signature technique to provide a patient-specific femur
Study: NCT00148278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norepinephrine and dobutamine
Description: continuous infusion of norepinephrine titrated to maintain a mean arterial pressure at 70mmHg or more and dobutamine could be added as a continuous infusion when cardiac index was of less than 2.5 liters per squared meter of body surface

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epinephrine plus placebo of dobutamine
Description: epinephrine was titrated to maintain a mean arterial pressure at 70mmHg or more and placebo of dobutamine was titrated in case of a cardiac index lower than 2.5 liters per squared meters of body surface
Study: NCT02428361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biologically active human fecal material, OpenBiome
Description: Fecal microbiota transplant
Study: NCT04522895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Participants receive up to 12 cycles of Enasidenib.
Study: NCT00435409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib + Capecitabine
Description: Sunitinib administered orally at a starting dose of 37.5 mg once a day on a continuous regimen.~Capecitabine administered orally at a starting dose of 2000 mg/m\^2 per day \[1000 mg/m\^2 bid (twice daily)\] from days 1-14 every 3 weeks. Study treatment should be given until progression or withdrawal from the study for other reasons.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine administered orally at a starting dose of 2500 mg/m\^2 per day \[1250 mg/m\^2 bid (twice daily)\] from days 1-14 every 3 weeks. Study treatment should be given until progression or withdrawal from the study for other reasons. At the time of progression, patients may be eligible to crossover to single agent sunitinib, administered orally at a starting dose of 37.5 mg daily.
Study: NCT04474470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT219
Description: Dose escalation of NT219 as a single agent in adult subjects with recurrent and/or metastatic solid tumors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT219 and ERBITUX® - Dose Escalation
Description: Dose escalation of NT219 in combination with standard dose ERBITUX® in adult subjects with recurrent and/or metastatic squamous cell carcinoma of the head and neck and colorectal adenocarcinoma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT219 and ERBITUX® - Expansion
Description: Expansion cohort of NT219 at its RP2D in combination with standard dose ERBITUX® in adult patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
Study: NCT04687475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Tool (Mobile Spirometry and Survey)
Description: The clinical tool is a combination of home spirometry measurements and a patient survey measuring patient reported outcomes including the Cystic Fibrosis Respiratory Symptom Diary (CFRSD) and Chronic Respiratory Infection Symptom Score (CRISS©), with permission from the Seattle Quality of Life Group.
Study: NCT02381561

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropidoxuridine
Description: Given PO
Study: NCT03564600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aging Back Clinics management
Description: Personalized care is delivered that is guided by published algorithms for each component condition identified by a trained provider.
Study: NCT01231984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4 mm x 32G Pen Needle
Description: During the 12 week study period, subjects use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. Subjects are advised to inject straight in when using the 4mm PN, with no pinch up.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4 mm x 32G Pen Needle
Description: During the 12 week study period, subjects use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. Subjects are advised to inject straight in when using the 4mm PN, with no pinch up.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 8mm x 31G Pen Needle
Description: During the 12 week study period, subjects will use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. Subjects are directed to use pinch-up when injecting in the abdomen or thigh with the 8mm PN, and no pinch-up at other injection sites.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 12.7mm x 29G Pen Needle
Description: During the 12 week study period, subjects will use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. When using the 12.7mm PN, subjects are instructed to insert either at an angle of 45 degrees, or to pinch up and hold the pen device at a 90 degree angle (straight in).
Study: NCT03541850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiandrogen Therapy
Description: Receive luteinizing hormone-releasing hormone agonist or gonadotropin-releasing hormone antagonist, and oral anti-androgen

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT03261271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Program
Description: Program involves one-on-one coaching, diet meal plan, and physical activity plan.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized educational flyer
Description: The American Institute for Cancer Research handout Nutrition and the Cancer Survivor will be provided to participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Maintenance Program
Description: Post-surgery program involves group support sessions, phone check-ins, and diet and exercise monitoring.
Study: NCT02325596

Intervention type: GENETIC
Intervention: miRNA mimics or inhibitors
Description: DCs are transfected by the miRNA mimics or inhibitors after they are separated from peripheral blood mononuclear cells in CRS patients

Intervention type: GENETIC
Intervention: miRNA mimics or inhibitors
Description: DCs are transfected by the miRNA mimics or inhibitors after they are separated from peripheral blood mononuclear cells in CRS patients

Intervention type: GENETIC
Intervention: miRNA mimics or inhibitors
Description: DCs are transfected by the miRNA mimics or inhibitors after they are separated from peripheral blood mononuclear cells in CRS patients

Intervention type: GENETIC
Intervention: miRNA mimics or inhibitors
Description: DCs are transfected by the miRNA mimics or inhibitors after they are separated from peripheral blood mononuclear cells in CRS patients
Study: NCT00642200

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lichtenstein hernioplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic TEP
Study: NCT03316781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX03
Description: 80 mg SC at Week 0, 40 mg SC at Week 1, and 40 mg every other week thereafter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: 80 mg SC at Week 0, 40 mg SC at Week 1, and 40 mg every other week thereafter.
Study: NCT01584869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: capsule endoscopy
Study: NCT04780867

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed vaccination
Description: First and second hepatitis B vaccinations will be delayed by 1 month in the interventional group to establish whether changes in psychosocial and lifestyle factors during training impact immune health.
Study: NCT00759590

Intervention type: PROCEDURE
Intervention: CT scan and Pressure volume curve
Description: CT scan
Study: NCT00907426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% solution
Description: Once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin).

Intervention type: DRUG
Group type: OTHER
Intervention: Bimatoprost 0.03% solution
Description: Once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin).

Intervention type: DRUG
Group type: OTHER
Intervention: Bimatoprost 0.03% solution
Description: Once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin).

Intervention type: DRUG
Group type: OTHER
Intervention: Vehicle solution
Description: Once daily, one drop of vehicle solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin).

Intervention type: DRUG
Group type: OTHER
Intervention: Vehicle solution
Description: Once daily, one drop of vehicle solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin).
Study: NCT04252911

Intervention type: OTHER
Intervention: Bispectral index score
Description: Bis value from two sites gives similar results
Study: NCT02455245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin and Vincristine
Description: Carboplatin 175 mg/m2 IV infusion Vincristine 1.5mg/m2 IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin and Vincristine
Description: Carboplatin 175 mg/m2 IV infusion Vincristine 1.5mg/m2 IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin 560 mg/m2 (or 19 mg/kg for children weighing less than 12 kg) IV
Study: NCT03028766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: AZD1775 is a potent, selective small molecule inhibitor of WEE1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: AZD1775 is a potent, selective small molecule inhibitor of WEE1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Chemotherapy drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Chemotherapy drug

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Intensity Modulated Radiotherapy
Study: NCT02218372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fidaxomicin oral suspension
Description: Participants from birth to \< 6 years of age received weight based doses of fidaxomicin oral suspension (32 mg/kg/day with a maximum dose of 400 mg/day divided in 2 doses) 2 times daily for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fidaxomicin tablets
Description: Participants aged ≥ 6 years to \< 18 years of age received a 200 mg fidaxomicin tablet 2 times daily for 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin oral liquid
Description: Participants from birth to \< 6 years of age received weight based doses of vancomycin oral liquid (40 mg/kg/day with a maximum dose of 500 mg/day divided in 4 doses) 4 times daily for 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin capsules
Description: Participants aged ≥ 6 years to \< 18 years of age received a 125 mg vancomycin capsule 4 times daily for 10 days.
Study: NCT03957954

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cLSC
Description: Transplantation of cLSC

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Scleral contact lens (SCL)
Description: Scleral contact lens device (SCL) will be used to stabilize and improve ocular surface.
Study: NCT01481922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whitacre 24 gauge
Description: Whitacre 24 gauge spinal needle 3 inches 1/2. Manufactured by Becton Dickinson

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: whitacre 22 gauge
Description: Whitacre 22 gauge spinal needle 3 inches 1/2 manufactured by Becton Dickinson
Study: NCT02182622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Study: NCT02340793

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Counterweight Plus
Description: A non-surgical, nutritionally replete weight management programme comprising a Total Diet Replacement Plan (TDR) of 800+ calories/day to produce a weight loss of \>15kg over 12-20 weeks; followed by a structured Food Reintroduction phase for 6-8 weeks and a Weight Loss Maintenance phase; total intervention period 2 years.
Study: NCT01598935

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: nutrition
Description: protein-based food

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutrition
Description: protein-based food

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutrition
Description: protein-based food

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutrition
Description: protein-based food
Study: NCT01962935

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD4721
Description: Part A - multiple ascending dose, daily; Part B - one dose decided after part A, daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4721
Description: Part A - multiple ascending dose, daily; Part B - one dose decided after part A, daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part A - multiple ascending dose daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD5069
Description: Part B - one dose decided after part A, twice a day
Study: NCT01184586

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention - ESWT Storz Duolith high energy
Description: Three weekly sessions of extracorporeal shockwave therapy with focussed shock waves (2000 impulses, 0,35-1,25mJ/mm2)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CONTROL SHAM-ESWT Storz Duolith [0.01mJ/mm2]
Description: Three weekly sessions of sham extracorporeal shock wave (2000 impulses, 0,01mJ/mm2)
Study: NCT01612338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted
Description: Targeted letter and booklet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Tailored
Description: Tailored letter and booklet, enhanced family communication and support brochure
Study: NCT00436332

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Study: NCT04638907

Intervention type: PROCEDURE
Intervention: Assessment of NM block
Description: Observation of resulting course of NM block under teratment and monitoring as described.
Study: NCT05360069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Linear stapler
Description: Linear stapler is adopted in esophagojejunostomy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Circular stapler
Description: Circular stapler is adopted in esophagojejunostomy